Core Insights - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for treating bradykinin-mediated diseases, including hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][9] Business Updates - The company is on track to report data from the pivotal Phase 3 trial, RAPIDe-3, in Q4 2025, with additional data from the CHAPTER-3 trial expected in the second half of 2026 [2][3] - The recently initiated CREAATE study aims to evaluate deucrictibant for both prophylactic and on-demand treatment of AAE-C1INH attacks [3][4] - Pharvaris has a strong financial position with cash and cash equivalents of €329 million as of September 30, 2025, compared to €281 million at the end of 2024 [11] Development Pipeline - Topline data for RAPIDe-3, a Phase 3 study of deucrictibant immediate-release capsule for on-demand treatment of HAE attacks, is expected in Q4 2025 [3][4] - Enrollment in CHAPTER-3, a Phase 3 study of deucrictibant extended-release tablet for prophylaxis against HAE attacks, is progressing as planned, with topline data anticipated in the second half of 2026 [3][4] - The CREAATE study has been initiated to assess the efficacy and safety of deucrictibant for AAE-C1INH attacks, with a structured approach to treatment [4] Financial Performance - For Q3 2025, R&D expenses were €29.8 million, up from €25.8 million in Q3 2024, while G&A expenses decreased to €9.8 million from €12.1 million in the same period [11] - The company reported a loss of €37.1 million for Q3 2025, resulting in a basic and diluted loss per share of €0.60, compared to a loss of €41.7 million and a loss per share of €0.77 in Q3 2024 [11]